Why the study?
The association between clonal hematopoiesis of indeterminate potential (CHIP) and specific coronary lesions in CKD patients was unreported, and its relationship with cardiovascular events remained controversial.
Does the presence of CHIP increase the risk of severe coronary lesions and adverse clinical events in patients with CKD undergoing coronary angiography?
Population
151 CKD patients who underwent coronary angiography
Comparison
CHIP vs non-CHIP
Design
Prospective cohort study
Key result
The presence of clonal hematopoiesis of indeterminate potential in patients with chronic kidney disease was independently associated with an increased risk of adverse clinical events (HR 2.02; 95% CI 1.11-3.67; P=0.022).
Authors
Loading...
Hypothesis-generating for CHIP in cardiorenal risk; prospective trials needed before clinical adoption.
Cohort (n=151)
Does the presence of CHIP increase the risk of severe coronary lesions and adverse clinical events in patients with CKD undergoing coronary angiography?
Effect estimate: HR 2.02 (95% CI 1.11-3.67)
p-value: p=0.022
In patients with CKD undergoing coronary angiography, the presence of CHIP is independently associated with more severe coronary lesions and a higher risk of adverse clinical events.
Liu et al. (2026) conducted a cohort in Chronic kidney disease (n=151). Clonal hematopoiesis of indeterminate potential (CHIP) vs. Non-CHIP was evaluated on Primary composite endpoint (HR 2.02, 95% CI 1.11-3.67, p=0.022). The presence of clonal hematopoiesis of indeterminate potential in patients with chronic kidney disease was independently associated with an increased risk of adverse clinical events (HR 2.02; 95% CI 1.11-3.67; P=0.022).